Protagonist Therapeutics (PTGX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Key Insights
Critical company metrics and information
Share Price
$40.58Market Cap
$2.42 BillionTotal Outstanding Shares
59.60 Million SharesTotal Employees
126Dividend
No dividendIPO Date
August 11, 2016SIC Description
Pharmaceutical PreparationsHomepage
https://www.protagonist-inc.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $22.35 Million |
| Net Cash Flow From Investing Activities | $-352.05 Million |
| Net Cash Flow | $-99.41 Million |
| Net Cash Flow From Operating Activities, Continuing | $230.29 Million |
| Net Cash Flow From Investing Activities, Continuing | $-352.05 Million |
| Net Cash Flow From Operating Activities | $230.29 Million |
| Net Cash Flow, Continuing | $-99.41 Million |
| Net Cash Flow From Financing Activities, Continuing | $22.35 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Income/Loss | $149.11 Million |
| Net Income/Loss | $170.85 Million |
| Diluted Earnings Per Share | $2.74 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Diluted Average Shares | $65.83 Million |
| Operating Expenses | $174.68 Million |
| Basic Average Shares | $62.53 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income Tax Expense/Benefit | $2.23 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $173.08 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $170.85 Million |
| Research and Development | $132.12 Million |
| Other Operating Expenses | $42.56 Million |
| Net Income/Loss Attributable To Parent | $170.85 Million |
| Revenues | $323.80 Million |
| Income/Loss From Continuing Operations After Tax | $170.85 Million |
| Basic Earnings Per Share | $2.86 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $531.91 Million |
| Assets | $603.86 Million |
| Liabilities And Equity | $603.86 Million |
| Current Liabilities | $44.58 Million |
| Other Current Liabilities | $41.53 Million |
| Noncurrent Assets | $127.09 Million |
| Other Non-current Assets | $124.62 Million |
| Fixed Assets | $2.47 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities | $71.94 Million |
| Equity Attributable To Parent | $531.91 Million |
| Current Assets | $476.77 Million |
| Noncurrent Liabilities | $27.36 Million |
| Accounts Payable | $3.05 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.